About the Authors
- Matthias Kern
-
Affiliation Department of Medicine, University of Leipzig, Leipzig, Germany
- Nora Klöting
-
Affiliation IFB Obesity Diseases, Junior Research Group Animal Models, University of Leipzig, Leipzig, Germany
- Heiko G. Niessen
-
Affiliation Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- Leo Thomas
-
Affiliation Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- Detlef Stiller
-
Affiliation Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- Michael Mark
-
Affiliation Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- Thomas Klein
-
Affiliation Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- Matthias Blüher
-
* E-mail: bluma@medizin.uni-leipzig.de
Affiliation Department of Medicine, University of Leipzig, Leipzig, Germany
Competing Interests
L. Thomas, H. G. Niessen, D. Stiller, T. Klein, and M. Mark are employees of Boehringer Ingelheim Pharma. Linagliptin is a Boehringer Ingelheim Pharma product. There are no other patents, products in development or other marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MK NK MB. Performed the experiments: MK NK HGN LT MM DS MB. Analyzed the data: MK NK TK MB. Contributed reagents/materials/analysis tools: HGN LT DS MM TK. Wrote the paper: MK NK TK MB.